BMY Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Bristol-Myers Squibb Co (BMY) is not a strong buy for a beginner investor with a long-term focus at this time. While the company has a strong pipeline and positive financial performance, the lack of immediate positive trading signals, insider selling, and cautious sentiment from Congress members suggest waiting for a more favorable entry point.
The stock's technical indicators are mixed. While moving averages are bullish (SMA_5 > SMA_20 > SMA_200), the MACD is negatively expanding (-0.162), and RSI is neutral at 44.337. The stock is trading near its support level (S1: 60.106), but there is no clear upward momentum.
Strong Q4 financial performance with revenue up 1.30% YoY, net income up 1409.72% YoY, and EPS up 1225.00% YoY.
Positive pipeline developments, including high-profile Phase 3 catalysts expected in
Analysts have raised price targets recently, with several maintaining Buy or Overweight ratings.
Insider selling has increased significantly (up 15753.10% in the last month).
Congress members have shown a cautious attitude, with 4 sale transactions and no purchases in the last 90 days.
The stock experienced a -2.55% regular market decline, and pre-market trends show further weakness (-0.30%).
In Q4 2025, Bristol-Myers Squibb reported strong financial growth. Revenue increased by 1.30% YoY to $12.5 billion, net income surged by 1409.72% YoY to $1.087 billion, and EPS rose by 1225.00% YoY to $0.53. Gross margin also improved by 8.43% YoY to 65.34%.
Analysts are cautiously optimistic about the stock. While RBC Capital sees a balanced risk/reward profile, Piper Sandler, Barclays, Guggenheim, and others have raised price targets and highlighted the company's strong pipeline. However, concerns about patent expirations (Eliquis and Opdivo) and macro factors persist, with some analysts maintaining Neutral or Underweight ratings.
